Description
ATX-304 is a synthetic small molecule research compound characterized as a direct pan-AMPK (AMP-activated protein kinase) activator, developed by Betagenon AB (Sweden) and currently in Phase 2 clinical research for metabolic research applications. AMPK is a heterotrimeric protein kinase widely regarded as the master regulator of cellular energy metabolism, with three subunits (α, β, γ) that combine into multiple isoforms (α1β1γ1, α2β1γ1, α2β2γ3, and others). ATX-304 has been characterized in academic research literature as a direct pan-AMPK activator — binding to the AMPK ADaM (allosteric drug and metabolite) site and activating all AMPK isoform combinations, distinguishing it from earlier AMPK research tools such as AICAR (which activates AMPK indirectly via AMP-mimetic mechanisms) and A-769662 (which activates only β1-containing AMPK isoforms). The compound has been investigated in preclinical and clinical research literature for AMPK pathway pharmacology, mitochondrial biogenesis research, fat oxidation research, and glucose homeostasis research in cell and preclinical research models. This 100mg oral capsule format is offered strictly for laboratory research applications investigating direct pan-AMPK activator pharmacology, comparative research versus other AMPK-targeted research compounds, and metabolic pathway research. The oral capsule format uses microcrystalline cellulose (MCC) as the standard capsule excipient in a gelatin capsule shell.
Benefits (Research Focus)
• Direct pan-AMPK activation research — studied as a direct allosteric AMPK activator binding the ADaM site with activity across all AMPK isoform combinations
• AMPK pathway pharmacology — investigated for AMPK downstream signaling cascade research including ACC phosphorylation and downstream metabolic gene expression
• Mitochondrial biogenesis research — explored for AMPK-mediated PGC-1α activation and mitochondrial biogenesis pathway endpoints
• Comparative AMPK research — examined alongside AICAR (indirect AMPK activation) and other AMPK research compounds for comparative SAR studies
• Pan-isoform AMPK research — researched as an isoform-nonselective research tool activating all α/β/γ subunit combinations, distinguishing from isoform-selective AMPK research compounds
What Researchers Look At
• AMPK phosphorylation status (Thr172) and downstream ACC (acetyl-CoA carboxylase) phosphorylation endpoints
• PGC-1α gene expression and mitochondrial biogenesis pathway markers
• Fat oxidation and lipid metabolism endpoints in cell research models
• Glucose uptake and glucose homeostasis endpoints
• Comparative pharmacology versus AICAR, A-769662, MK-8722, and other AMPK research compounds
Quick Specs
• Form: Gelatin capsule
• Strength: 50 mg ATX-304 per capsule
• Quantity: 30 capsules per bottle
• Total ATX-304 per Bottle: 1,500 mg (1.5 g)
• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell
• Appearance: Standard gelatin capsule presentation
• Purity: ≥99%
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: ATX-304
• Synonyms: O304 (academic literature designation); Betagenon AMPK activator research compound; pan-AMPK activator
• Class: Synthetic small molecule; direct pan-AMPK activator; ADaM-site allosteric AMPK activator; oral metabolic research compound
• Mechanism: Direct allosteric activation of AMPK via binding at the ADaM (allosteric drug and metabolite) site; activates all AMPK isoform combinations (α1/α2 × β1/β2 × γ1/γ2/γ3)
• Originator: Betagenon AB (Sweden) — small-molecule metabolic research compound developer
• Clinical research status: Phase 2 clinical research for metabolic research applications
• Molecular Weight: Verify against batch COA
• CAS: Verify against batch COA (novel compound; commodity database values may vary by source)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications by FDA, Health Canada, or any regulatory authority.
- Investigational research compound only — ATX-304 remains in active Phase 2 clinical research and has not been evaluated for long-term safety in humans.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates. For novel compounds like ATX-304, we prioritize structural verification via mass spectrometry against published academic literature.
Third-Party Testing
• [COA links for the ATX-304 100mg × 30 capsule batch to be added once analytical testing is complete]
